Literature DB >> 20639266

Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?

Diederik P C de Rooy1, Michael P M van der Linden, Rachel Knevel, Tom W J Huizinga, Annette H M van der Helm-van Mil.   

Abstract

OBJECTIVES: In order to allow personalized medicine, adequate prediction of disease outcome is required. In early undifferentiated arthritis (UA), prediction of the development of RA is crucial, and in case of RA predicting the severity of the disease course may guide individualized treatment decisions.
METHODS: A total of 570 UA patients and 676 RA patients included in the Leiden Early Arthritis Clinic cohort were studied for baseline characteristics. The disease outcomes studied were fulfillment of the 1987 ACR-RA criteria and arthritis persistence in UA patients and the rate of radiological joint destruction and achieving sustained DMARD-free remission in RA patients.
RESULTS: Predictive factors for fulfillment of the 1987 ACR-RA criteria and for persistent arthritis in UA were largely similar. Risk factors for a severe rate of joint destruction were: older age (P<0.001); male gender (P<0.001); longer symptom duration at first visit (P=0.048), involvement of lower extremities (P<0.001); BMI (P<0.001); high acute phase reactants, presence of IgM-RF (P<0.001); anti-CCP2 antibodies (P<0.001); anti-modified citrullinated vimentin antibodies (P<0.001) and HLA-DRB1 shared epitope alleles (P=0.001). A high BMI was associated with a lower rate of joint destruction but with a higher risk of disease persistence. The proportion of variance in joint destruction explained was 32%
CONCLUSION: Predictors for RA development, previously used to develop a prediction rule in UA patients, are largely similar to predictors for arthritis persistency. Only part of the joint destruction level in RA is explained by the currently known risk factors. New factors need to be identified in order to guide pharmaceutical intervention at the level of individual RA patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639266     DOI: 10.1093/rheumatology/keq230

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  80 in total

1.  Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Authors:  Jing Shi; Rachel Knevel; Parawee Suwannalai; Michael P van der Linden; George M C Janssen; Peter A van Veelen; Nivine E W Levarht; Annette H M van der Helm-van Mil; Anthony Cerami; Tom W J Huizinga; Rene E M Toes; Leendert A Trouw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

2.  Rheumatoid Arthritis: Early diagnosis and treatment outcomes.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2011

3.  Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis.

Authors:  Aleid C Boer; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2018-01-08       Impact factor: 19.103

Review 4.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

5.  Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?

Authors:  Wouter Stomp; Annemarie Krabben; Désirée van der Heijde; Tom W J Huizinga; Johan L Bloem; Mikkel Østergaard; Annette H M van der Helm-van Mil; Monique Reijnierse
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

Review 6.  The epidemiology of early inflammatory arthritis.

Authors:  Johanna M W Hazes; Jolanda J Luime
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

7.  Association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in rheumatoid arthritis, independent of the shared epitope alleles but not independent of anti-citrullinated protein antibodies.

Authors:  H W van Steenbergen; S Raychaudhuri; L Rodríguez-Rodríguez; S Rantapää-Dahlqvist; E Berglin; R E M Toes; T W J Huizinga; B Fernández-Gutiérrez; P K Gregersen; A H M van der Helm-van Mil
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

8.  Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis.

Authors:  Anouk van Hooij; Debbie M Boeters; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Paul L A M Corstjens; Annette H M van der Helm-van Mil; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

9.  Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.

Authors:  Georgia Barouta; Christina G Katsiari; Ioannis Alexiou; Christos Liaskos; Areti Varna; Dimitrios P Bogdanos; Anastasios E Germenis; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2016-12-10       Impact factor: 2.980

Review 10.  Strategies to predict rheumatoid arthritis development in at-risk populations.

Authors:  Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2014-08-04       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.